Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 8/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.53 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.53 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.47 |
| ▸ | SELE | P16581 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.43 |
| ▸ | SLC9A1 | P19634 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6089315 | 0.86 | CLK1 (0.53) | CLK1DYRK1ADYRK1BICAM1SELE | |
| SCHEMBL6329461 | 0.84 | HDAC3 (0.57) | CLK1DYRK1ADYRK1BICAM1SELE | |
| SCHEMBL6330056 | 0.80 | CLK1 (0.57) | CLK1DYRK1ADYRK1BICAM1SELE | |
| SCHEMBL5584284 | 0.79 | HDAC3 (0.52) | DYRK1AICAM1SELEHDAC3HDAC4 | |
| SCHEMBL11888470 | 0.78 | CLK1 (0.69) | CLK1DYRK1ADYRK1BHDAC3HDAC4 | |
| SCHEMBL5584759 | 0.74 | HDAC3 (0.46) | CLK1DYRK1ADYRK1BICAM1SELE | |
| SCHEMBL7928289 | 0.72 | CLK1 (0.74) | CLK1DYRK1ADYRK1BCLK2CLK4 | |
| SCHEMBL22116287 | 0.71 | CA12 (0.55) | CLK1DYRK1ADYRK1BCA2TRPM8 | |
| SCHEMBL14594121 | 0.70 | CLK1 (0.54) | CLK1DYRK1ADYRK1BICAM1SELE | |
| SCHEMBL30682899 | 0.70 | CLK1 (0.49) | CLK1DYRK1ADYRK1BICAM1SELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7196199-B2 | Antiserotonine agents; antidepressants | MITSUBISHI PHARMA CORPORATION (JP) | 2007-03-27 | — | — | US | disclosed |
| EP-1188747-B1 | PHENOXYPROPYLAMINE COMPOUNDS | MITSUBISHI PHARMA CORP (JP) | 2005-09-07 | — | — | EP | disclosed |
| US-20040138227-A1 | Phenoxypropylamine compounds | NISHIYAMA AKIRA | 2004-07-15 | — | — | US | disclosed |
| US-6720320-B2 | ANTISEROTONINE AGENTS | MITSUBISHI PHARMA CORPORATION (JP) | 2004-04-13 | — | — | US | disclosed |
| US-20020111358-A1 | Phenoxypropylamine compounds | MITSUBISHI PHARMA CORPORATION (JP) | 2002-08-15 | — | — | US | disclosed |
| EP-1188747-A1 | PHENOXYPROPYLAMINE COMPOUNDS | Mitsubishi Pharma Corporation (JP) | 2002-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138227-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | CLK1 2498/4885DYRK1A 958/4885DYRK1B 1061/4885 |
| US-20020111358-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | CLK1 2498/4885DYRK1A 958/4885DYRK1B 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.